Search

everythinglearnresearchcommunity

for

Search:↓

Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.

JAK inhibitors are effective for hair regrowth in severe alopecia areata.

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.

JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.

Rituximab treatment led to complete hair regrowth and improved skin in a woman with pemphigus foliaceus.

Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.

Aggressive immunosuppressive treatment improved a woman's severe heart condition linked to autoimmune disease.

Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.

Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.

Oral tofacitinib may effectively treat hair loss in children with alopecia areata.

Combining fractionated CO2 laser with tacrolimus may help treat chronic alopecia areata.

Rituximab effectively treated a woman's bone lymphoma that was resistant to other treatments.

FilaggrinHigh melanomas have active FGFR signaling and weak GNA14 and Th1 signatures.

Topical tofacitinib may help regrow hair in children with alopecia totalis.

Upadacitinib effectively treats psoriasis and lichen planus together.

Janus kinase inhibitors may help treat lichen planopilaris.

Bimekizumab effectively treated a man's chronic beard hair loss.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

Dupilumab can help hair regrowth but may also trigger alopecia areata.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.

Mogamulizumab can cause hair loss and skin rashes.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Targeting CD200 could be a new treatment for rheumatoid arthritis.

Alefacept does not effectively treat severe alopecia areata.

ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.